A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy

References

• Aderibigbe OR, Pisa PT, Mamabolo RL, et al. (2011). The relationship between indices of iron status and selected anthropometric cardiovascular disease risk markers in an African population: the THUSA study. Cardiovasc J Afr 22:249–56
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Sundaram C, Malani N, Ichikawa H. (2007). Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1–75
   PubMed Web of Science ®Google Scholar
• Ahluwalia N, Genoux A, Ferrieres J, et al. (2010). Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr 140:812–16
   PubMed Web of Science ®Google Scholar
• Altamura S, Muckenthaler MU. (2009). Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis 16:879–95
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, et al. (2004). Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127:348–55
   PubMed Web of Science ®Google Scholar
• Aruoma OI, Bomford A, Polson RJ, Halliwell B. (1988). Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. Blood 72:1416–19
   PubMedGoogle Scholar
• Baccan MM, Chiarelli-Neto O, Pereira RM, Esposito BP. (2012). Quercetin as a shuttle for labile iron. J Inorg Biochem 107:34–9
   PubMed Web of Science ®Google Scholar
• Bae YJ, Yeon JY, Sung CJ, et al. (2009). Dietary intake and serum levels of iron in relation to oxidative stress in breast cancer patients. J Clin Biochem Nutr 45:355–60
   PubMedGoogle Scholar
• Balan V, Baldus W, Fairbanks V, et al. (1994). Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 107:453–9
   PubMed Web of Science ®Google Scholar
• Bareggi SR, Cornelli U. (2012). Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther 18:41–6
   PubMed Web of Science ®Google Scholar
• Brissot P, Ropert M, Le Lan C, Loreal O. (2012). Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403–10
   PubMed Web of Science ®Google Scholar
• Bush AI. (2002). Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol Aging 23:1031–8
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. (2005). LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18:277–87
   PubMed Web of Science ®Google Scholar
• Cooper GJ. (2011). Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer’s disease. Drugs 71:1281–320
   PubMed Web of Science ®Google Scholar
• Du XX, Xu HM, Jiang H, et al. (2012). Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease. Neurosci Bull 28:253–8
   PubMed Web of Science ®Google Scholar
• Duguid JB. (1946). Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 58:207–12
   PubMedGoogle Scholar
• Esposito BP, Breuer W, Sirankapracha P, et al. (2003). Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:2670–7
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, et al. (2010). Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466–75
   PubMed Web of Science ®Google Scholar
• Fenton HJH. (1894). Oxidation of tartaric acid in presence of iron. J Chem Soc 64:899–910
   Google Scholar
• Fiorani M, de Sanctis R, de Bellis R, Dacha M. (2002). Intracellular flavonoids as electron donors for extracellular ferricyanide reduction in human erythrocytes. Free Radic Biol Med 32:64–72
   PubMed Web of Science ®Google Scholar
• Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ. (2012). Iron mobilization using chelation and phlebotomy. J Trace Elem Med Biol 26:127–30
   PubMedGoogle Scholar
• Gackowski D, Kruszewsk M, Banaszkiewicz Z, et al. (2002). Lymphocyte labile iron pool, plasma iron, transferrin saturation and ferritin levels in colon cancer patients. Acta Biochim Pol 49:269–72
   PubMed Web of Science ®Google Scholar
• Gackowski D, Kruszewski M, Jawien A, et al. (2001). Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med 31:542–7
   PubMedGoogle Scholar
• Galaris D, Pantopoulos K. (2008). Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit Rev Clin Lab Sci 45:1–23
   PubMed Web of Science ®Google Scholar
• Glickstein H, El RB, Shvartsman M, Cabantchik ZI. (2005). Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106:3242–50
   PubMed Web of Science ®Google Scholar
• Grootveld M, Bell JD, Halliwell B, et al. (1989). Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis: characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264:4417–22
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. (1990). Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186:1–85
   PubMed Web of Science ®Google Scholar
• Haust MD, Wyllie JC, More RH. (1964). Atherogenesis and plasma constituents. I: demonstration of fibrin in the white plaque by the fluorescent antibody technique. Am J Pathol 44:255–67
   PubMedGoogle Scholar
• Hodkova A, Cerna P, Kotyzova D, Eybl V. (2010). The effect of iron(III) on the activity of selenoenzymes and oxidative damage in the liver of rats. Interaction with natural antioxidants and deferiprone. Hemoglobin 34:278–83
   PubMed Web of Science ®Google Scholar
• Jomova K, Valko M. (2011a). Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87
   PubMed Web of Science ®Google Scholar
• Jomova K, Valko M. (2011b). Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des 17:3460–73
   PubMed Web of Science ®Google Scholar
• Jomova K, Valko M. (2012). Redox cycling mechanisms in the colon. Med Hypotheses 79:418–19
   PubMedGoogle Scholar
• Jomova K, Vondrakova D, Lawson M, Valko M. (2010). Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345:91–104
   PubMed Web of Science ®Google Scholar
• Kell DB. (2009). Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2:2 doi: 10.1186/1755-8794-2-2
   PubMed Web of Science ®Google Scholar
• Kell DB. (2010). Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84:825–89
   PubMed Web of Science ®Google Scholar
• Kim EY, Ham SK, Shigenaga MK, Han O. (2008). Bioactive dietary polyphenolic compounds reduce nonheme iron transport across human intestinal cell monolayers. J Nutr 138:1647–51
   PubMed Web of Science ®Google Scholar
• Kovacevic Z, Kalinowski DS, Lovejoy DB, et al. (2011). The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 11:483–99
   PubMed Web of Science ®Google Scholar
• Kruszewski M. (2003). Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531:81–92
   PubMed Web of Science ®Google Scholar
• Kruszewski M. (2004). The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 51:471–80
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL. (2011). Management of transfusional iron overload – differential properties and efficacy of iron chelating agents. J Blood Med 2:135–49
   PubMedGoogle Scholar
• Lipinski B, Nowak A, Gurewich V. (1974). The organ distribution of 125I-fibrin in the generalized Shwartzman reaction and its relation to leucocytes. Br J Haematol 28:221–31
   PubMed Web of Science ®Google Scholar
• Lipinski B, Pretorius E. (2012). Novel pathway of ironinduced blood coagulation: implications for diabetes mellitus and its complications. Pol Arch Med Wewn 122:115–22
   PubMed Web of Science ®Google Scholar
• Ma Y, De Groot H, Liu Z, et al. (2006). Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem J 395:49–55
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhou T, Kong X, Hider RC. (2012). Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19:2816–27
   PubMed Web of Science ®Google Scholar
• Mak JC. (2012). Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol 39:265–73
   PubMed Web of Science ®Google Scholar
• Marx G, Chevion M. (1985). Fibrinogen coagulation without thrombin: reaction with vitamin C and copper(II). Thromb Res 40:11–18
   PubMed Web of Science ®Google Scholar
• Millerot-Serrurot E, Bertrand N, Mossiat C, et al. (2008). Temporal changes in free iron levels after brain ischemia Relevance to the timing of iron chelation therapy in stroke. Neurochem Int 52:1442–8
   PubMed Web of Science ®Google Scholar
• More RM, Movat HZ, Haust DM. (1957). Role of mural fibrin thrombi of the aorta in genesis of arteriosclerotic plaques; report of two cases. Arch Pathol 63:612–20
   Google Scholar
• Perron NR, Brumaghim JL. (2009). A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 53:75–100
   PubMed Web of Science ®Google Scholar
• Petrat F, de Groot H, Sustmann R, Rauen U. (2002). The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem 383:489–502
   PubMed Web of Science ®Google Scholar
• Piga A, Longo F, Duca L, et al. (2009). High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 84:29–33
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Breuer W, Sametband M, et al. (2004). Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 104:1504–10
   PubMed Web of Science ®Google Scholar
• Porter JB, Rafique R, Srichairatanakool S, et al. (2005). Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Ann NY Acad Sci 1054:155–68
   PubMed Web of Science ®Google Scholar
• Robello E, Galatro A, Puntarulo S. (2009). Labile iron pool and ferritin content in developing rat brain gamma-irradiated in utero. Neurotoxicology 30:430–5
   PubMed Web of Science ®Google Scholar
• Shah SV, Rajapurkar MM. (2009). The role of labile iron in kidney disease and treatment with chelation. Hemoglobin 33:37–85
   PubMedGoogle Scholar
• Shah SV, Rajapurkar MM, Houser, M. (2008). The role of labile iron in acute kidney injury. US Nephrology 3:52–5
   Google Scholar
• Shainoff JR, Page IH. (1972). Deposition of modified fibrinogen within the aortic intima. Atherosclerosis 16:287–305
   PubMedGoogle Scholar
• Small BG, Mccoll BW, Allmendinger R, et al. (2011). Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol 7:902–8
   PubMedGoogle Scholar
• Smith EB. (1994). Lipids and plasma fibrinogen: early and late composition of the atherosclerotic plaque. Cardiologia 39:169–72
   PubMedGoogle Scholar
• Smith EB, Alexander KM, Massie IB. (1976). Insoluble “fibrin” in human aortic intima: quantitative studies on the relationship between insoluble “fibrin”, soluble fibrinogen and low density lipoprotein. Atherosclerosis 23:19–39
   PubMedGoogle Scholar
• Srichairatanakool S, Ounjaijean S, Thephinlap C, et al. (2006). Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin 30:311–27
   PubMed Web of Science ®Google Scholar
• Stadler N, Lindner RA, Davies MJ. (2004). Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24:949–54
   PubMed Web of Science ®Google Scholar
• Taher A, Musallam KM, El Rassi F, et al. (2009). Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 146:569–72
   PubMed Web of Science ®Google Scholar
• Tanaka K, Miyake Y, Fukushima W, et al. (2011). Intake of Japanese and Chinese teas reduces risk of Parkinson’s disease. Parkinsonism Relat Disord 17:446–50
   PubMed Web of Science ®Google Scholar
• Tijburg LB, Mattern T, Folts JD, et al. (1997). Tea flavonoids and cardiovascular disease: a review. Crit Rev Food Sci Nutr 37:771–85
   PubMed Web of Science ®Google Scholar
• Uchida T, Akitsuki T, Kimura H, et al. (1983). Relationship among plasma iron, plasma iron turnover, and reticuloendothelial iron release. Blood 61:799–802
   PubMed Web of Science ®Google Scholar
• Vlachodimitropoulou E, Sharp PA, Naftalin RJ. (2011). Quercetin-iron chelates are transported via glucose transporters. Free Radic Biol Med 50:934–44
   PubMedGoogle Scholar
• Wang T, Qin L, Liu B, et al. (2004). Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 88:939–47
   PubMed Web of Science ®Google Scholar
• Wardman P, Candeias LP. (1996). Fenton chemistry: an introduction. Radiat Res 145:523–31
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Mandel S, Youdim MB. (2009a). Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 4:283–96
   PubMed Web of Science ®Google Scholar
• Weinreb O, Mandel S, Bar-Am O, et al. (2009b). Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics 6:163–74
   PubMed Web of Science ®Google Scholar
• Whitnall M, Richardson DR. (2006). Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13:186–97
   PubMedGoogle Scholar
• Woolf N. (1961). The distribution of fibrin within the aortic intima: an immunohistochemical study. Am J Pathol 39:521–32
   PubMedGoogle Scholar
• Yu Y, Gutierrez E, Kovacevic Z, et al. (2012). Iron chelators for the treatment of cancer. Curr Med Chem 19:2689–702
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Chow BK, Howes PS, et al. (2008). Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100:996–1002
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Shamayeva G, Chow BK. (2011). Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 162:949–57
   PubMed Web of Science ®Google Scholar